Pathophysiological impact of Nevro HFX™ high-frequency (10 kHz) spinal cord stimulation for painful diabetic neuropathy
June 25 from 10:15 am — 11:00 am PDT
Supported By: Nevro Corp.
Program Description
24-month results from the largest randomized controlled trial studying spinal cord stimulation (SCS) in patients with painful diabetic neuropathy (PDN) will be presented. In addition, we will be reviewing new data highlighting the comprehensive, long-term efficacy of high-frequency SCS therapy in providing profound pain relief, reversing loss of protective sensation in the feet, and significantly reducing HbA1c and weight.
Learn how 10 kHz Therapy™ fits into the 2022 recommendations from the American Diabetes Association Diagnosing and Treatment of Painful Diabetic Peripheral Neuropathy Compendia and the American Association of Clinical Endocrinology Diabetes Guideline Update. You won’t want to miss this interdisciplinary expert presentation across endocrine and neurosurgery specialties. We will be reviewing the patient benefits of 10 kHz Therapy that are driving the cross-functional recommendations of the effective treatments for refractory PDN to conventional medical management1
10 kHz Therapy™ spinal cord stimulation is a unique treatment option provided by Nevro products. This evidence-based, non-drug innovation has impacted the lives of more than 100,000 patients globally. Nevro HFX™ is approved by the FDA as a treatment for patients suffering from painful diabetic neuropathy, non-surgical back pain, and failed back surgery syndrome.
Nevro HFX™ is available in the United States, Australia, Austria, Germany, Italy, Luxembourg, Netherlands, Switzerland, Sweden, and the United Kingdom.
1 Peterson, E., et al. (2021). Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: A randomized clinical trial. JAMA Neurology, 78(6), 687–698.
Speakers
David C. Klonoff MD, FACP, FRCP, Fellow AIMBE
Mills-Peninsula Medical Center
Endocrinology, Diabetes and Metabolism
Medical Director, Diabetes Research Institute
Burlingame, CA
UCSF
Department of Medicine
Clinical Professor
San Francisco, CA
Journal of Diabetes Science and Technology
Editor and Chief
Newbury Park, CA
Erika A. Petersen MD, FAANS, FACS
UAMS Medical Center
Department of Neurosurgery
Neurosurgeon / Program Director, Neurosurgery Residency Program / Professor, Director of Functional & Restorative Neurosurgery and Neuromodulation
Little Rock, AR